Drag Pharma [upd] | Simple & Fresh

As investors and executives, we must stop asking "Is this drug safe?" and start asking "What is the drag coefficient?" Because a cure that arrives 5 years late is not a cure—it is a business decision.

This post is structured for a professional audience (LinkedIn, industry blog, or investor newsletter) but is written to be accessible to anyone following biotech. In the golden era of genetic medicine and AI-driven discovery, it takes an average of 10-15 years and $2.6 billion to bring a single drug to market. While we often blame the science for this timeline, a growing body of evidence points to a different culprit: Drag Pharma. drag pharma

"Drag Pharma" describes the strategic, operational, and regulatory inertia that incumbents (Big Pharma) use to protect market share, or the unintended consequences of bureaucracy that stifle innovation. It is the art of not moving quickly. As investors and executives, we must stop asking

No, this isn't a new autoimmune disease. It is the silent, systemic friction that slows down the drug development pipeline—often deliberately. While we often blame the science for this

Disclaimer: This post is for informational purposes only and does not constitute legal or investment advice.